Company Overview - Zhiyun Health (09955.HK) is a leading provider of digital chronic disease management solutions in China, established in 2014 [3] - The company offers a comprehensive range of services including hospital SaaS systems, pharmacy SaaS systems, and advanced internet hospital platforms, covering the entire lifecycle of digital chronic disease management [3] - Zhiyun Health serves over 2,700 hospitals and more than 219,000 pharmacies nationwide, integrating upstream and downstream in the industry chain [3] Financial Performance - As of December 31, 2024, Zhiyun Health reported total revenue of 3.488 billion yuan, a year-on-year decrease of 5.49% [2] - The company experienced a net loss attributable to shareholders of 516 million yuan, a significant decline of 59.85% year-on-year [2] - The gross profit margin stood at 24.7%, with a debt-to-asset ratio of 49.63% [2] Market Performance - On July 7, the stock closed at 1.18 HKD per share, marking an increase of 8.26% with a trading volume of 5.484 million shares and a turnover of 6.2606 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 3.81%, but it has declined by 9.17% year-to-date, underperforming the Hang Seng Index by 19.22% [2] Valuation Metrics - Currently, there are no institutional investment ratings for Zhiyun Health [2] - The company's price-to-earnings (P/E) ratio is -1.26, ranking 99th in the industry, while the average P/E ratio for the healthcare equipment and services sector is -2.82 [2] - Comparatively, other companies in the sector have P/E ratios ranging from 0.29 to 5.2 [2]
智云健康（09955.HK）7月7日收盘上涨8.26%，成交626.06万港元